Krebs MG, Cho BC, Hiret S, Han JY, et al. Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study. J Thorac Oncol 2025 May 16:S1556-0864(25)00720.
PMID: 40383434